All articles
Articleoverviewpeptidesrecovery

Strength peptides 101: a clear-eyed introduction

What strength peptides are, what categories matter, what works, and where the marketing gets ahead of the evidence. The plain-English orientation.

May 7, 2026 · 5 min read · By Strength Peptide Editors


If you've heard about BPC-157, TB-500, Ipamorelin, or "the recovery stack" and want a serious overview without the bro-science, this is the orientation. We'll walk through what strength peptides actually are, the categories that matter, what works, and where marketing exceeds science.

What "strength peptides" actually means

The phrase covers a loose category of peptide compounds used in athletic, recovery, and biohacking contexts. Practically, it boils down to three families:

FamilyExamplesWhat it does
Recovery / healingBPC-157, TB-500Tendon, ligament, gut, soft-tissue repair
GH secretagoguesIpamorelin, CJC-1295, Sermorelin, Tesamorelin, MK-677Trigger your own pituitary to release more growth hormone
Skin / cosmeticGHK-CuSkin remodeling, wound healing, hair-follicle research

There's a fourth family that gets lumped in but is genuinely different: GLP-1 peptides (semaglutide, tirzepatide). Those are weight-loss drugs, not strength peptides. They're a separate category with their own science, dosing, and use cases.

What's not in scope

A few common misconceptions worth clearing up:

  • Synthetic HGH (somatropin) is not a peptide secretagogue. It's recombinant growth hormone — directly injected GH. Schedule III in the US, prescription-only.
  • Anabolic steroids are not peptides. They're modified hormones with completely different mechanisms.
  • SARMs are small-molecule androgen receptor modulators, not peptides.
  • Creatine, BCAAs, beta-alanine are amino acids and amino-acid derivatives, not peptides.

The three categories, explained

Recovery peptides

The two compounds that dominate this category are BPC-157 and TB-500.

BPC-157 is a 15-amino-acid synthetic peptide derived from a protein found in human gastric juice. It promotes angiogenesis (new blood vessel formation), upregulates growth factors at injury sites, and protects gastric tissue. Best documented in animal models for tendon, ligament, gut, and brain healing. Daily SubQ injection, typically 250–500 mcg.

TB-500 is a 17-amino-acid fragment of thymosin beta-4. It binds and regulates G-actin, the cytoskeletal protein, and signals systemic cell migration toward injury sites. Long tissue half-life — dosed twice weekly during loading, then every 1–2 weeks for maintenance.

The two are often stacked. BPC-157 acts locally; TB-500 acts systemically. For stubborn tendon or ligament injuries, the stack reportedly outperforms either alone. For acute, well-localized injuries, BPC-157 alone usually does the job.

What the research record actually shows: strong pre-clinical animal data, limited human clinical data. Both peptides are research chemicals — not FDA-approved for human use. BPC-157 was specifically rejected for compounding by FDA in late 2023.

GH secretagogues

Compounds that nudge your pituitary to release more of its own growth hormone, rather than replacing GH from the outside. Three subclasses:

  • GHRH analogues — mimic the natural GHRH signal. Examples: Sermorelin (closest to natural), CJC-1295, Tesamorelin (FDA-approved for HIV-LD).
  • Ghrelin mimetics (GHRPs) — bind the ghrelin receptor to amplify GH release. Examples: Ipamorelin (cleanest profile), GHRP-2/6 (older, more side effects), MK-677 (oral, technically not a peptide).
  • Combination — long-acting variants like CJC-1295 with DAC produce sustained elevation rather than discrete pulses.

The classic stack is Ipamorelin + CJC-1295 (no DAC), dosed 1–3 times daily SubQ. The two compounds activate complementary pathways and produce synergistic GH pulses.

How they differ from synthetic HGH: secretagogues amplify your body's natural pulsatile pattern and cap at what your pituitary can release. Synthetic HGH is flat, supraphysiologic, and suppresses feedback. Secretagogues are gentler — but the ceiling is lower too.

Skin / cosmetic peptides

Mostly GHK-Cu (a copper-binding tripeptide). Skin remodeling, wound healing, hair-follicle research applications. Topical or low-dose subcutaneous. Less directly performance-relevant but often grouped with strength peptides because of overlapping vendor channels and reconstitution similarities.

What actually works (with caveats)

Honest read of the evidence:

Use caseWhat works (per current evidence)
Tendon / ligament chronic injuryBPC-157, BPC-157 + TB-500 stack — strong pre-clinical, broad N-of-1 reports
Gut healing (IBD, ulcers)BPC-157 — most clinically-promising indication
Body composition for 30s+GH secretagogue cycles — modest but real effects
Sleep qualitySermorelin, CJC-1295 + Ipamorelin — frequently reported
Acute soft-tissue injuryBPC-157 alone — most reported
Dramatic muscle gainNone of these. Don't expect anabolic-steroid-class results from secretagogues.

What the marketing oversells

A few common claims to be skeptical about:

  • "BPC-157 heals everything." It's a recovery peptide, not a cure-all. Strong on tendon/gut, weak on neurological conditions, untested on most chronic diseases.
  • "GH secretagogues replace HGH." They don't. Different mechanism, different ceiling, different risk profile.
  • "Pharmaceutical-grade research peptides." No such thing. Pharmaceutical-grade is a regulatory category. Research chems are not.
  • "FDA-approved peptides." Outside of a small list (Tesamorelin, Sermorelin in some forms, a few others), they aren't.

A reasonable starting framework

If you're considering strength peptides:

  1. Start with one peptide, not a stack. Establish how your body responds.
  2. Pick the one matching your goal. Recovery → BPC-157. GH-axis support → Sermorelin or Ipa+CJC.
  3. Get baseline labs. Fasting glucose, A1C, lipid panel, basic metabolic, IGF-1 if running secretagogues.
  4. Buy from vendors with COAs. Identity, purity, and endotoxin testing are non-negotiable.
  5. Run a defined cycle. 4–8 weeks for recovery peptides, 12 weeks for secretagogues.
  6. Track effects in writing. Subjective and objective.
  7. Stop signals are real. Spreading rash, persistent severe headache, vision changes, cardiac symptoms, new lumps — discontinue immediately and seek care.
  8. Have a clinician in the loop. Even off-label, an informed clinician is an asset.

A few facts to set the context:

  • Most strength peptides are sold as research chemicals, not pharmaceutical products
  • BPC-157 specifically was rejected by FDA for 503A compounding in November 2023
  • Quality varies dramatically vendor-to-vendor
  • "FDA-approved" claims about any of these (other than Tesamorelin, certain Sermorelin formulations) are false
  • Importation rules vary by country; some research-chem channels operate in regulatory gray zones

This isn't a "don't use these" article. It is a "know what you're stepping into" article. Strength peptides have real mechanisms, plausible benefits, and real-but-mostly-mild side-effect profiles. They also have unsettled long-term safety questions and a messy supply chain. Both things are true.

The site you're reading exists to help users navigate that reality — without bro-science, without doom-mongering, and without selling anything.

Free weekly newsletter

Get the strength peptide highlights, weekly.

One short email a week — new guides, study readouts, supply updates, and dosing tips. Plain-English, no spam.

Unsubscribe anytime. We never share your email.